Scoop has an Ethical Paywall
Living Cell Technologies - Latest News [Page 5]
LCT announces $6.4m capital placement
Tuesday, 30 October 2007, 12:19 am | Living Cell Technologies
30 October 2007, Auckland, New Zealand and Melbourne, Australia: Living Cell Technologies Ltd (ASX:LCT, OTC: LVCLY) announces that it has closed a further private placement bringing a total of $6.4million in additional share capital to the company. More >>
Further Positive Preliminary Data on DiabeCell®
Monday, 22 October 2007, 3:16 pm | Living Cell Technologies
22 October 2007, Auckland, New Zealand and Melbourne, Australia: Living Cell Technologies Ltd (ASX:LCT, OTC: LVCLY) is releasing this update on the excellent initial responses observed in its DiabeCell® trial in Russia to ensure that the information is available ... More >>
LCT To Raise $2.4 Million With Other Options
Wednesday, 3 October 2007, 2:50 pm | Living Cell Technologies
Living Cell Technologies Ltd (ASX:LCT; OTC: LVCLY) today signed a non-binding letter of intent for the sale of up to AUD$9.8 million in ordinary shares by clients of US-based investment group, NaviGroup Management Ltd. More >>
Approval for DiabeCell® Clinical Trial in NZ
Wednesday, 12 September 2007, 12:05 am | Living Cell Technologies
LCT receives Regional Ethics Committee approval for diabetes clinical trial in NZ * LCT pig cell transplant diabetes phase I/IIa trial on track to start by end of 2007 * LCT is the only company world-wide to obtain clinical trial approval for a ... More >>
Scientific Journal Endorses DiabeCell® Therapy
Wednesday, 1 August 2007, 12:01 am | Living Cell Technologies
Living Cell Technologies Limited (ASX: LCT; US OTC: LVCLY) today announced the publication of a scientific paper endorsing the micro-encapsulation technology used in the cell-based therapeutic product, DiabeCell®. More >>
Living Cell Technologies Enhances US Capabilities
Monday, 2 July 2007, 11:46 am | Living Cell Technologies
Living Cell Technologies Limited (ASX:LCT) today announced the appointment of Robert J. Beckman, Dr. Allan R. Goldberg and Philip N. Sussman, Managing Partners of The Channel Group, LLC (TCG), a New York based life science venture development and management ... More >>
Diabetes Transplant Success In World-First Trial
Thursday, 14 June 2007, 2:51 pm | Living Cell Technologies
Living Cell Technologies Ltd (ASX:LCT) is pleased to announce it has successfully transplanted the first of six type I (insulin dependent) diabetic patients in a world-first. More >>
LCT diabetes clinical programme to proceed
Tuesday, 17 April 2007, 11:44 am | Living Cell Technologies
Company announcement Living Cell Technologies Ltd ABN: 14 104 028 042 17 April 2007 Auckland, New Zealand and Melbourne, Australia More >>
Diabetes Clinical Programme to Proceed
Tuesday, 17 April 2007, 12:38 am | Living Cell Technologies
Living Cell Technologies Ltd (ASX:LCT) after rigorous international review has received authorization from the New Zealand regulator MedSafe to advance its program to conduct a Phase I/IIa clinical trial of its DiabeCell® diabetes product in New Zealand. More >>
Xenotransplant trial in diabetes w/o immunisation
Tuesday, 30 January 2007, 2:31 pm | Living Cell Technologies
A product made from natural neonatal pig islet cells encased in capsules is to offer new hope to people with type 1 (insulin-dependent) diabetes. In a world first, Australian-listed company, Living Cell Technologies (LCT), is poised to start a Phase I/IIa trial for ... More >>
LCT Reports Positive Meetings With FDA And Medsafe
Thursday, 16 February 2006, 5:29 pm | Living Cell Technologies
Living Cell Technologies Limited (ASX:LCT) today reported it has held positive meetings with the US Food and Drug Administration (FDA) and New Zealand’s MedSafe, regarding its NeurotrophinCell and DiabeCell products. More >>
Cell Therapy Supported by Bioethics Recommendation
Thursday, 15 December 2005, 9:50 am | Living Cell Technologies
Living Cell Technologies (ASX: LCT) welcomes the final recommendation by Toi te Taiao: the Bioethics Council, that xenotransplantation should be allowed to develop in New Zealand. More >>
